Successful Removal of Aluminium From Patient With Dialysis Encephalopathy

Ackrill, P.; Ralston, A. J.; Day, John; Hodge, K.C.

doi:10.1016/s0140-6736(80)92728-2

Cited by 215 publications

(47 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1978; Brun & Dictor, 1981;Scholtz et al 1987). Further evidence implicating A1 as a cause of dialysis encephalopathy is neurological improvement with the 130 G. L. K L E I N A1 chelator desferrioxamine, provided treatment is begun early (Alfrey, 1986;Ackrill et al 1986).…”

Section: I a L Y S I S E N C E P H A L O P A T H Ymentioning

confidence: 99%

Nutritional Aspects of Aluminium Toxicity

Klein

1990

Nutr. Res. Rev.

View full text Add to dashboard Cite

Table 1. Parenteral sources of aluminium contamination A1 Wl) Source Casein hydrolysate (100 g/l) Crystalline amino acids (100 g/l) Potassium phosphate (3 mmol/l) Unspecified phosphate Potassium phosphate Potassium acid phosphate (136 g/l) Sodium phosphate (3 mmol/l) Calcium gluconate (100 g/l) Calcium glucoheptonate Normal serum albumin (250 g/l) Normal serum albumin (43 g/l) Plasmanate? (50 g/l) Heparin (lo00 u/ml) Factor VIII Factor IX Trace metal solutions Multivitamin infusion

show abstract

Section: I a L Y S I S E N C E P H A L O P A T H Ymentioning

confidence: 99%

Nutritional Aspects of Aluminium Toxicity

Klein

1990

Nutr. Res. Rev.

View full text Add to dashboard Cite

show abstract

“…relataram o emprego bem sucedido deste agente quelante de ferro no tratamento da intoxicação alumínica. 27 A desferroxamina é uma sideroamina natural obtida a partir da cultura da bactéria Streptomyces pilosus. 28 Sua substância ativa, o mesilato ou metanossulfato de desferroxamina B, apresenta enorme afinidade pelo ferro trivalente, com capacidade de removê-lo da ferritina e da hemossiderina, mas não da hemoglobina.…”

Section: Racionalunclassified

Intoxicação alumínica na DRC

Barreto¹,

Araújo²

2011

J. Bras. Nefrol.

View full text Add to dashboard Cite

“…The effectiveness of DFO in chelating iron and Al overload [5] and the dramatic effects of this drug in the treatment of dialysis encephalopathy [1,5] and Al-related disorders has led to its widespread use in dialysis units. In general.…”

Section: Case Reportmentioning

confidence: 99%

“…The chelating agent desferrioxamine (DFO) has been successfully used in the treatment of dialysis encephalo pathy [1] and other Al-related disorders in patients on long-term hemodialysis. This drug has been regarded as having minimal side effects.…”

mentioning

confidence: 99%

Desferrioxamine-Induced Acute Neurosensorial Deafness

Sabater

et al. 1988

Nephron

View full text Add to dashboard Cite

Successful Removal of Aluminium From Patient With Dialysis Encephalopathy

Cited by 215 publications

References 4 publications

Nutritional Aspects of Aluminium Toxicity

Nutritional Aspects of Aluminium Toxicity

Intoxicação alumínica na DRC

Desferrioxamine-Induced Acute Neurosensorial Deafness

Contact Info

Product

Resources

About